ReShape Lifesciences announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office, USPTO, for patent application 18/370,819, entitled, “Intragastric Device.” When issued, the patent will cover claims for an intragastric balloon system, comprising a capsule configured to be swallowable by a patient and to degrade in a gastric environment, with a balloon compacted and contained within the capsule, the balloon including an outer and inner surface, an interior cavity, a fill valve and release valve wherein the fill valve and release valves are separate valves, among other claim features. Once issued, the patent will provide protection into at least January 2031, without accounting for a potential Patent Term Extension.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RSLS:
- ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System
- RSLS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX
- ReShape Lifesciences announces cost reduction plan, reorganization
- ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX